Last reviewed · How we verify
NCT03975205: Doxil
To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames
EARLY_PHASE1 trial testing Doxorubicin in Lymphoma Leukemia in 500 participants. Status unknown.
31 October 2019
Quick facts
| Lead sponsor | Sutphin Drugs |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 500 |
| Start date | 1 July 2019 |
| Primary completion | 31 October 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across India |
Drugs / interventions tested
- Doxorubicin (doxorubicin) — full drug profile →
Conditions studied
- Lymphoma Leukemia — all drugs for Lymphoma Leukemia →
Sponsor
Sutphin Drugs — full company profile →
Who can join
Adults 18 to 75, any sex, with Lymphoma Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03975205
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Doxorubicin
Trials testing the same drug.
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
- NCT07493148 — Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL · Phase 2 · recruiting
- NCT07278856 — Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphoma · Phase 1 · not yet recruiting
Other Sutphin Drugs trials
Trials by the same sponsor.
- NCT04502277 — Bioavailability of Flucanazole · EARLY_PHASE1 · unknown
- NCT04113772 — Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine · NA · unknown
- NCT03975374 — To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03975205 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sutphin Drugs
- Last refreshed: 5 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03975205.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing